Oncothyreon, Inc. has announced initiation of a Phase II clinical trial of the company’s investigational agent PX-866 in the treatment of men with chemotherapy-naïve, recurrent or metastatic, castration-resistant prostate cancer (CRPC). The trial is being conducted by the NCIC Clinical Trials Group (NCIC CTG), headquartered at Queen’s University in Kingston, Ontario, Canada.
PX-866 is an inhibitor of an important cell signaling pathway that is commonly activated in many types of human cancer (the so-called PI-3K/PTEN/AKT pathway). Abnormal activation and regulation of phosphoinositide 3-kinase (PI-3K) occurs in several human cancers. Such abnormal activation and regulation can lead to proliferation of cancer cells and inhibition of programmed cell death (apoptosis). PX-866 is a small molecule that can be taken orally. More information about this drug can be found on the Oncothyreon web site.
Detailed information about this clinical trial is available on the ClinicalTrials.gov web site. The trial is already enrolling patients but is open exclusively to men with castration-resistant prostate cancer who have received no prior chemotherapy treatment for recurrent disease. It is not yet entirely clear at which centers in Canada that patients can be enrolled into this trial.
Filed under: Drugs in development, Management Tagged: | castration-resistant, inhibitor, kinase, metastatic, Oncothyreon, PX-866
Search for new and
ongoing trials on the
CTAG PCa web site
